Is There Use for FDG-PET in Prostate Cancer?

Jadvar, Hossein

doi:10.1053/j.semnuclmed.2016.07.004

Cited by 136 publications

(93 citation statements)

References 35 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 F FDG is not a new tracer but is the most common PET radiotracer commercially available for oncological use. However, its utility in prostate adenocarcinoma is confined to aggressive, poorly differentiated disease (Figure 13) [116, 117]. Several novel imaging agents have been developed in the last decade that show a better ability to identify malignancy.…”

Section: Nuclear Medicine Imaging In Prostate Adenocarcinomamentioning

confidence: 99%

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Bagheri

Ahlman

Lindenberg

et al. 2017

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Medical imaging of the three most common genitourinary (GU) cancers—prostate adenocarcinoma, clear cell renal cell carcinoma (RCC), and urothelial carcinoma of the bladder—has evolved significantly during the past decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector CT and multiparametric MRI (mpMRI) with diffusion-weighted imaging are the main imaging modalities for RCC and urothelial carcinoma, and while mpMRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose (FDG)-PET, and sodium fluoride (NaF)-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review will provide an overview of the latest advances in the imaging of these three major GU cancers.

show abstract

Section: Nuclear Medicine Imaging In Prostate Adenocarcinomamentioning

confidence: 99%

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Bagheri

Ahlman

Lindenberg

et al. 2017

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

show abstract

“…The multifocal distribution of cancer deposits mixed with noncancerous cells and the proximity of the gland to the urinary bladder are also limiting factors. Therefore, generally, FDG PET has no significant role in the localization of primary prostate cancer [105]. …”

Section: Imaging In Focal Therapymentioning

confidence: 99%

Multimodal imaging in focal therapy planning and assessment in primary prostate cancer

Jadvar

2017

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

Purpose There is increasing interest in focal therapy (male lumpectomy) of localized low-intermediate risk prostate cancer. Focal therapy is typically associated with low morbidity and provides the possibility of retreatment. Imaging is pivotal in stratification of men with localized prostate cancer for active surveillance, focal therapy or radical intervention. This article provides a concise review of focal therapy and the evolving role of imaging in this clinical setting. Methods We performed a narrative and critical literature review by searching PubMed/Medline database from January 1997 to January 2017 for articles in the English language and the use of search keywords “focal therapy”, “prostate cancer”, and “imaging”. Results Most imaging studies are based on multiparametric magnetic resonance imaging. Transrectal ultrasound is inadequate independently but multiparametric ultrasound may provide new prospects. Positron emission tomography with radiotracers targeted to various underlying tumor biological features may provide unprecedented new opportunities. Multimodal Imaging appears most useful in localization of intraprostatic dominant index lesions amenable to focal therapy, in early assessment of therapeutic efficacy and potential need for additional focal treatments or transition to whole-gland therapy, and in predicting short-term and long-term outcomes. Conclusion Multimodal imaging is anticipated to play an increasing role in the focal therapy planning and assessment of low-intermediate risk prostate cancer and thereby moving this form of treatment option forward in the clinic.

show abstract

“…As far as PET is concerned, the most commonly used tracer, FDG (fludeoxyglucose), is not very useful. In fact, the coexistence of normal and tumor tissue, the high activity of the nearby bladder, and low glycolysis rate of the tumor could interfere with the precise localization of malignant cells . To overcome these drawbacks, various targeted agents are under development and, among them, the 68 Ga tracers are most interesting.…”

Section: Introductionmentioning

confidence: 99%

“…In fact, the coexistence of normal and tumor tissue, the high activity of the nearby bladder, and low glycolysis rate of the tumor could interfere with the precise localization of malignant cells. 7 To overcome these drawbacks, various targeted agents are under development and, among them, the 68 Ga tracers are most interesting. Without the need of a cyclotron, they are able to specifically visualize overexpressed receptors in the lesions such as gastrin releasing peptide receptor (GRPR) 8 and prostate-specific membrane antigene (PSMA).…”

Section: Introductionmentioning

confidence: 99%

An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma

Pagoto

Tripepi

Stefanìa

et al. 2018

Magnetic Resonance in Med

View full text Add to dashboard Cite

Purpose Prostate cancer (PCa) is the most widespread tumor affecting males in Western countries. We propose a novel MRI molecular tetrameric probe based on the heptadentate gadolinium (Gd)‐AAZTA (6‐amino‐6‐methylperhydro‐1,4‐diazepinetetraacetic acid) that is able to in vivo detect PCa through the recognition of the fibrin–fibronectin (FB–FN) complex. Methods The peptide CREKA (Cys‐Arg‐Glu‐Lys‐Ala), targeting the FB–FN complex in the reactive stroma of the tumor, was synthesized by solid phase peptide synthesis (SPPS) and conjugated to the tetramer dL‐(Gd‐AAZTA)4. The resulting probe was characterized by 1H relaxometry, tested in vitro on FB clots and in vivo on an orthotopic mouse model of PCa. Results CREKA‐dL‐(Gd‐AAZTA)4 showed a remarkable relaxivity of 18.2 mMGd-1s−1 (0.47 T, 25°C) because of the presence of 2 water molecules (q = 2) in the inner coordination sphere of each Gd3+ ion, whose rotational motion (τR) is lengthened as the result of the relatively high molecular weight. The probe displayed a detectable affinity for plasma‐derived FB clots. On intravenous injection of the probe in an orthotopic mouse model of PCa, a significant increase in the prostate T1 contrast (~40%) was observed. The MRI signal appears statistically higher either with respect to the one observed for the control probes and to the one detected when CREKA‐dL‐(Gd‐AAZTA)4 was administered to healthy animals. Conclusions This study demonstrated the ability of the CREKA‐dL‐(Gd‐AAZTA)4 probe to specifically localize in prostate tumor after injection. The high relaxivity of the probe allows the reduction of the injected dose to 20 µmolGd/kg, yielding a good in vivo contrast enhancement in the region of prostate tumor.

show abstract

Is There Use for FDG-PET in Prostate Cancer?

Cited by 136 publications

References 35 publications

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Multimodal imaging in focal therapy planning and assessment in primary prostate cancer

An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma

Contact Info

Product

Resources

About